AR092899A1 - Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion - Google Patents

Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion

Info

Publication number
AR092899A1
AR092899A1 ARP130103596A ARP130103596A AR092899A1 AR 092899 A1 AR092899 A1 AR 092899A1 AR P130103596 A ARP130103596 A AR P130103596A AR P130103596 A ARP130103596 A AR P130103596A AR 092899 A1 AR092899 A1 AR 092899A1
Authority
AR
Argentina
Prior art keywords
cancer
masitinib
populations
sub
treatment
Prior art date
Application number
ARP130103596A
Other languages
English (en)
Inventor
Pierre Kinet Jean
- Piquemal David Moussy Alain
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of AR092899A1 publication Critical patent/AR092899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Reivindicación 1: Un método para el tratamiento del cáncer en un paciente humano, caracterizado porque dicho método comprende administrar a un paciente humano que lo necesita al menos un inhibidor de tirosina quinasa, inhibidor de mastocitos o inhibidor de c-Kit.
ARP130103596A 2012-10-04 2013-10-04 Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion AR092899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12306214 2012-10-04

Publications (1)

Publication Number Publication Date
AR092899A1 true AR092899A1 (es) 2015-05-06

Family

ID=47073382

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103596A AR092899A1 (es) 2012-10-04 2013-10-04 Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion

Country Status (20)

Country Link
US (1) US10238649B2 (es)
EP (1) EP2903616B8 (es)
JP (1) JP6234466B2 (es)
KR (1) KR102149483B1 (es)
CN (1) CN104968347A (es)
AR (1) AR092899A1 (es)
AU (1) AU2013326463B2 (es)
BR (1) BR112015007144A2 (es)
CA (1) CA2886979C (es)
DK (1) DK2903616T3 (es)
EA (1) EA037368B1 (es)
ES (1) ES2656640T3 (es)
IL (1) IL238107B (es)
MX (1) MX369999B (es)
NZ (1) NZ706420A (es)
SG (1) SG11201502626PA (es)
SI (1) SI2903616T1 (es)
TW (1) TWI609686B (es)
WO (1) WO2014053650A1 (es)
ZA (1) ZA201503054B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052103A1 (en) * 2013-10-04 2016-08-10 AB Science Method for determining the prognosis of pancreatic cancer
BR112016026046A8 (pt) * 2014-05-08 2021-07-20 Oncoethix Gmbh uso de compostos de tienotriazolodiazepina
WO2016062267A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 奈必洛尔在制备抑制癌症的医药组合物中的用途
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
DK3423105T3 (da) 2016-03-02 2021-07-26 Eisai R&D Man Co Ltd Antistof-lægemiddelkonjugater på basis af eribulin og fremgangsmåder til anvendelse heraf
DK3240538T3 (da) * 2016-03-25 2021-12-06 Ab Science Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose
CN107267454A (zh) * 2016-04-07 2017-10-20 北京京蒙高科干细胞技术有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
EP3571200B8 (en) 2017-01-17 2022-08-03 HepaRegeniX GmbH Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3052190A1 (en) * 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
WO2020092240A1 (en) * 2018-10-29 2020-05-07 Northwestern University Big data-driven personalized management of chronic pain
WO2020115108A1 (en) * 2018-12-06 2020-06-11 Sørlandet Sykehus Hf Egfr inhibitors and their use in the treatment of neuroathic pain
WO2020115261A1 (en) * 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CN114214396A (zh) * 2020-06-30 2022-03-22 宁波市康宁医院(宁波市精神疾病预防控制中心、宁波市微循环与莨菪类药研究所) Gabrd甲基化作为抗***复吸靶点的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450302B2 (en) * 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
CA2494695C (en) 2002-08-02 2011-04-05 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
EP1913160A2 (en) 2005-07-29 2008-04-23 Bayer Healthcare LLC Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
WO2008115300A1 (en) * 2006-12-01 2008-09-25 Apocell, Inc. C-kit phosphorylation in cancer
US8227470B2 (en) 2007-01-12 2012-07-24 Ab Science Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
US8153792B2 (en) 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
WO2011056963A1 (en) 2009-11-04 2011-05-12 The University Of North Carolina At Chapel Hill Methods and compositions for predicting survival in subjects with cancer
AR080096A1 (es) * 2010-02-01 2012-03-14 Ab Science Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
WO2012170640A1 (en) * 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Methods and compositions for trail-drug combination therapy

Also Published As

Publication number Publication date
ES2656640T3 (es) 2018-02-27
JP2015532296A (ja) 2015-11-09
EA037368B1 (ru) 2021-03-19
DK2903616T3 (da) 2018-01-29
CN104968347A (zh) 2015-10-07
JP6234466B2 (ja) 2017-11-22
SI2903616T1 (en) 2018-02-28
AU2013326463B2 (en) 2018-01-18
EP2903616B8 (en) 2018-02-07
AU2013326463A1 (en) 2015-04-16
US20150272945A1 (en) 2015-10-01
WO2014053650A1 (en) 2014-04-10
TW201414475A (zh) 2014-04-16
SG11201502626PA (en) 2015-05-28
EA201500373A1 (ru) 2016-02-29
BR112015007144A2 (pt) 2017-12-12
IL238107B (en) 2018-03-29
MX2015004264A (es) 2015-10-12
NZ706420A (en) 2018-08-31
ZA201503054B (en) 2016-11-30
MX369999B (es) 2019-11-28
KR102149483B1 (ko) 2020-08-28
EP2903616A1 (en) 2015-08-12
KR20150092739A (ko) 2015-08-13
CA2886979A1 (en) 2014-04-10
TWI609686B (zh) 2018-01-01
US10238649B2 (en) 2019-03-26
EP2903616B1 (en) 2017-12-13
CA2886979C (en) 2021-01-05

Similar Documents

Publication Publication Date Title
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CL2016000373A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
SG10201902664RA (en) Combination therapy for treating cancer
BR112015012295A8 (pt) Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
BR112013024525A2 (pt) compostos, composição farmacêutica e métodos para tratar condição pré-cancerosa ou câncer em mamífero, pacientes com doença inflamatória crônica ou doença neurodegenerativa e para preparar compostos e usos de compostos e de composição farmacêutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure